Dementia pugilistica

Summary

Dementia pugilistica (MONDO:0019976) is a disease and 18 clinical trials. Top therapeutic interventions include florbetapir f 18 and flortaucipir f 18. A subtype of dementia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 18

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	dementia pugilistica
Mondo ID	MONDO:0019976
MeSH	D020208
Orphanet	97353
DOID	DOID:0081291
SNOMED CT	230283005
UMLS	C0149843
MedGen	508441
GARD	0019371
Is cancer (heuristic)	no

Also known as: Boxer’s dementia · chronic traumatic encephalopathy · punch-drunk syndrome

Disease family

This is a subtype of dementia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › dementia › dementia pugilistica

Related subtypes (8): vascular dementia, Alzheimer disease, Lewy body dementia, hereditary dementia, parkinsonism with dementia of Guadeloupe, AIDS dementia complex, progressive dementia with neuroserpin inclusion bodies, childhood-onset dementia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	3
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06254469	PHASE3	RECRUITING	Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer’s Disease
NCT02079766	PHASE2	COMPLETED	18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
NCT02191267	PHASE2	COMPLETED	Tau Imaging of Chronic Traumatic Encephalopathy
NCT03944447	PHASE2	UNKNOWN	Outcomes Mandate National Integration With Cannabis as Medicine
NCT02103894	PHASE1	COMPLETED	Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT05490576	PHASE1	UNKNOWN	Tau And Connectomics In TES Study
NCT02795052	Not specified	RECRUITING	Neurologic Stem Cell Treatment Study
NCT03218332	Not specified	RECRUITING	Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study
NCT06860828	Not specified	ENROLLING_BY_INVITATION	The DIAGNOSE CTE Research Project-II
NCT07302503	Not specified	RECRUITING	Pilot Study Evaluating brainQuant’s Ability to Detect Alterations in White Matter in Diffusion MRI, Indicative of Post-traumatic Lesions
NCT01891383	Not specified	WITHDRAWN	Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
NCT02266563	Not specified	COMPLETED	Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
NCT02798185	Not specified	COMPLETED	The DIAGNOSE-CTE Research Project
NCT03724136	Not specified	UNKNOWN	Alzheimer’s Autism and Cognitive Impairment Stem Cell Treatment Study
NCT04489082	Not specified	UNKNOWN	Near-Infrared Laser Stimulation for Various Neurological Conditions
NCT04796207	Not specified	COMPLETED	The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes
NCT04928534	Not specified	COMPLETED	Cohort Study of Blood Biomarkers for TES
NCT05235802	Not specified	UNKNOWN	Long-term Follow-up in Severe Traumatic Brain Injury

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLORBETAPIR F 18	4	1
FLORTAUCIPIR F 18	4	1